1-(4-乙基-2-吡啶基)乙酮 | 59576-27-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(4-乙基-2-吡啶基)乙酮
• 英文名称: 2-acetyl-4-ethylpyridine
• 英文别名: 2-Acetyl-4-ethyl-pyridin；1-(4-ethyl-[2]pyridyl)-ethanone；1-(4-Aethyl-[2]pyridyl)-aethanon；1-(4-Ethylpyridin-2-yl)ethanone
• CAS: 59576-27-1
• 化学式: C₉H₁₁NO
• 分子量: 149.192
• InChiKey: DEGKNYBGTWJELS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-乙基-2-吡啶基)乙酮 在 氢溴酸 、 溴 、 potassium carbonate 、 溶剂黄146 作用下， 以 丙酮 为溶剂， 反应 27.0h， 生成 methyl {2-[(4-ethylpyridin-2-yl)carbonyl]-5-(trifluoromethoxy)-1H-indol-3-yl}acetate
  参考文献：
  名称：

  Novel acid-type cyclooxygenase-2 inhibitors: Design, synthesis, and structure–activity relationship for anti-inflammatory drug

  摘要：

  Cyclooxygenase (COX) is a key rate-limiting enzyme for prostaglandin (PG) production cascades in the human body. The mechanisms of both the anti-inflammation effects and the side-effects of traditional COX inhibitors are associated with the existence of two COX isoforms. Thus while COX-1 is predominantly expressed ubiquitously and constitutively, and it serves a housekeeping role in processes such as gastrointestinal (GI) mucosa protection, COX-2 is absent or exhibits a low level of expression in most tissues, and is highly upregulated in response to endotoxin, virus, inflammatory or tissue-injury stimuli/signals, and tumour promoter in the various types of organs, tissues, and cells. Furthermore, COX-2 contribution to PGE(2) and PGI(2) production evokes and sustains systemic or peripheral inflammatory disease, but it is not involved in the COX-1-mediated GI tract events. Also, hypersensitivity of aspirin owing to its inhibitory action against COX-1 is a significant concern clinically. Consequently, highly selective COX-2 inhibitors have been needed for the treatment of inflammatory- and inflammation related-diseases that include pyrexia, inflammation, pain, rheumatoid arthritis, osteoarthritis, and cancers. In this study, a series of novel [2-{[(4-substituted or 4,5-disubstituted)-pyridin-2-yl]carbonyl}-(5- or 6-substituted or 5,6-disubstituted)-1H-indol-3-yl]acetic acid analogues was designed, synthesized, and evaluated to identify potent and selective COX-2 inhibitors as potential agents against inflammatory diseases. As significant findings, the present study clarified unique structure activity relationship of the analogues toward potent and selective COX-2 inhibition in vitro, and identified 2-{6-fluoro-2-[4-methyl-2-pridinyl)carbonyl]-1H-indol-3-yl}acetic acid as a potent and selective COX-2 inhibitor in vitro that demonstrated orally potent anti-inflammation efficacy against carrageenan-induced oedema formation in the foot of SPF/VAF male SD rats as a peripheral inflammation model in vivo. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.01.053
• 作为产物：
  描述：

  2-氨基-4-乙基吡啶 在 乙醚 、 氢溴酸 、 溴 、 sodium nitrite 、 苯 作用下， 生成 1-(4-乙基-2-吡啶基)乙酮
  参考文献：
  名称：

  The Preparation of Some Substituted 2,6-Bis-(2-pyridyl)-pyridines

  摘要：

  DOI：

  10.1021/ja01603a036

文献信息

• SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS
  申请人：Dahmann Georg

  公开号：US20130023502A1

  公开（公告）日：2013-01-24

  The invention relates to new substituted pyridinyl-pyrimidines of formula 1 wherein ring A is a five-membered saturated or unsaturated carbocyclic ring which optionally comprises one, two or three heteroatoms each independently from each other selected from the group N, S and O, wherein R 1 , R 2 , R 4 , R 3 , R 5 and R 6 are defined as in claim 1 and wherein ring A is further optionally substituted by one or two further substituents and the pharmaceutically acceptable salts, diastereomers, enantiomers, racemates, hydrates and solvates of the aforementioned compounds.

  该发明涉及公式1中的新取代吡啶基嘧啶化合物， 其中环A是一个含有五个成员的饱和或不饱和碳环，该环可选地包含一个、两个或三个异原子，每个异原子独立地选自N、S和O组成， 其中R1、R2、R4、R3、R5和R6如权利要求书中所定义，并且环A进一步可选地被一个或两个进一步取代基取代，以及上述化合物的药用盐、二对映体、对映体、消旋体、水合物和溶剂化合物。
• [EN] SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS<br/>[FR] PYRIDINYL-PYRIMIDINES SUBSTITUÉES ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012101013A1

  公开（公告）日：2012-08-02

  The invention relates to new substituted pyridinyl-pyrimidines of formula 1 wherein ring A is a five-membered saturated or unsaturated carbocyclic ring which optionally comprises one, two or three heteroatoms each independently from each other selected from the group N, S and O, wherein R1, R2, R4, R3, R5 and R6 are defined as in claim 1 and wherein ring A is further optionally substituted by one or two further substituents and the pharmaceutically acceptable salts, diastereomers, enantiomers, racemates, hydrates and solvates of the aforementioned compounds.

  该发明涉及公式1中的新取代吡啶基嘧啶，其中环A是一个五元饱和或不饱和碳环，可选地包含一个、两个或三个异原子，每个异原子独立地选自N、S和O组，其中R1、R2、R4、R3、R5和R6如权利要求1中所定义，环A进一步可选地被一个或两个进一步取代基取代，以及上述化合物的药学上可接受的盐、二对映体、对映体、消旋体、水合物和溶剂化合物。
• Steric Control of Directional Isomerism in Dicopper(I) Helicates of Asymmetrically Substituted 2,2‘:6‘,2‘‘:2‘‘,6‘‘‘-Quaterpyridine Derivatives
  作者：E. C. Constable、F. Heirtzler、M. Neuburger、M. Zehnder

  DOI：10.1021/ja9623626

  日期：1997.6.1

  Derivatives of 2,2':6',2'':2'',6'''-quaterpyridine have been prepared which are asymmetrically substituted with alkyl groups in the 4- or 6-position and with various substituents in the 4 '-position. These ligands form dicopper- (I) double helicates which have been investigated by 1 H and 13 C NMR spectroscopic techniques. The formation of helical isomers is shown to depend on the intramolecular interactions

  已经制备了 2,2':6',2'':2'',6'''-四联吡啶的衍生物，它们在 4-或 6-位被烷基不对称取代，在 4' 被各种取代基不对称取代-位置。这些配体形成二铜-(I)双螺旋体，已通过 1 H 和 13 C NMR 光谱技术对其进行了研究。显示螺旋异构体的形成取决于双螺旋的组成螺旋体之间的分子内相互作用；4'-甲基取代基与配对螺旋体的 4-取代基发生空间相互作用，导致选择性适中，尽管庞大的 4-取代基会降低选择性。在不存在 4'-取代基的情况下，较小的间距允许组分螺旋体的类似 4-取代基之间的空间相互作用。在每种情况下，
• [EN] NOVEL [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS [1.1.1] BICYCLO UTILISÉS COMME INHIBITEURS DE L'INDOLÉAMINE 2,3-DIOXYGÉNASE
  申请人：MERCK SHARP & DOHME

  公开号：WO2019204180A1

  公开（公告）日：2019-10-24

  Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

  本文披露了一种化合物(I)的结构，它们是IDO酶的抑制剂：(I)。本文还披露了这些化合物在潜在治疗或预防IDO相关疾病或紊乱中的用途。本文还披露了包含这些化合物的组合物。进一步披露了这些组合物在潜在治疗或预防IDO相关疾病或紊乱中的用途。
• [EN] 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS<br/>[FR] COMPOSES INDOLE 2,3-SUBSTITUES UTILISES COMME INHIBITEURS DE COX-2
  申请人：PFIZER PHARMACEUTICALS INC.

  公开号：WO1999035130A1

  公开（公告）日：1999-07-15

  (EN) This invention provides a compound of formula (I) or the pharmaceutically acceptable salts thereof wherein Z is OH, C1-6 alkoxy, -NR2R3 or heterocycle; Q is selected from the following: (a) an optionally substituted phenyl, (b) an optionally substituted 6-membered monocyclic aromatic group containing one, two, three or four nitrogen atom(s), (c) an optionally substituted 5-membered monocyclic aromatic group containing one heteroatom selected from O, S and N and optionally containing one, two or three nitrogen atom(s) in addition to said heteroatom, (d) an optionally substituted C3-7 cycloalkyl and (e) an optionally substituted benzofuzed heterocycle; R1 is hydrogen, C1-4 alkyl or halo; R2 and R3 are independently hydrogen, OH, C1-4 alkoxy, C1-4 alkyl or C1-4 alkyl substituted with halo, OH, C1-4 alkoxy or CN; X is independently selected from H, halo, C1-4 alkyl, halo-substituted C1-4 alkyl, OH, C1-4 alkoxy, halo-substituted C1-4 alkoxy, C1-4 alkylthio, NO2, NH2, di-(C1-4 alkyl)amino and CN; and n is 0, 1, 2, 3 and 4. This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.(FR) Cette invention porte sur un composé de la formule (I) ou sur les sels pharmaceutiquement acceptables de celui-ci, formule dans laquelle Z représente OH, alcoxy C1-6, -NR2R3 ou un hétérocycle; Q est sélectionné parmi: (a) un phényle éventuellement substitué, (b) un groupe aromatique monocyclique à 6 éléments éventuellement substitué contenant un, deux, trois ou quatre atomes d'azote, (c) un groupe aromatique monocyclique à 5 éléments éventuellement substitué contenant un hétéroatome sélectionné parmi O, S et N et contenant éventuellement un, deux ou trois atomes d'azote en plus de l'hétéroatome, (d) un cycloalkyle C3-7 éventuellement substitué et (e) un hétérocycle fusionné à benzo éventuellement substitué; R1 représente hydrogène, alkyle C1-4 ou halo; R2 et R3 représentent, indépendamment, hydrogène, OH, alcoxy C1-4, alkyle C1-4 ou alkyle C1-4 substitué par halo, OH, alcoxy C1-4 ou CN; X est indépendamment sélectionné parmi H, halo, alkyle C1-4, alkyle C1-4 halo-substitué, OH, alcoxy C1-4, alcoxy C1-4 halo-substitué, alkylthio C1-4, NO2, NH2, di-(C1-4alkyl)amino et CN; et n vaut 0, 1, 2, 3 et 4. Cette invention porte également sur une composition pharmaceutique utilisée dans le traitement d'un état pathologique dans lequel les prostaglandines sont impliquées comme agents pathogènes.

  该发明提供了式（I）的化合物或其药学上可接受的盐，其中Z代表OH，C1-6烷氧基，-NR2R3或杂环；Q从以下选取：（a）可选取取代苯基，（b）可选取含有一个、两个、三个或四个氮原子的6元单环芳香基，（c）可选取含有O、S和N中选取的一个杂原子的可选取取代的5元单环芳香基，并且除了所述杂原子外，还可含有一个、两个或三个氮原子，（d）可选取可选取取代的C3-7环烷基和（e）可选取取代的苯并杂环；R1代表氢、C1-4烷基或卤素；R2和R3独立地代表氢、OH、C1-4烷氧基、C1-4烷基或C1-4烷基取代的卤素、OH、C1-4烷氧基或CN；X独立地从H、卤素、C1-4烷基、卤素取代的C1-4烷基、OH、C1-4烷氧基、卤素取代的C1-4烷氧基、C1-4烷基硫、NO2、NH2、双（C1-4烷基）氨基和CN中选取；n为0、1、2、3和4。该发明还提供了一种药物组合物，用于治疗前列腺素作为病原体所涉及的医疗状况。